As activist Starboard teams up with former Pfizer executives, the pharma giant's lack of focus is in the spotlight.
Pfizer (PFE) shares have gained ground since theThe Wall Street Journal reported over the weekend that activist investor Starboard Value has taken a roughly $1 billion stake in the drug maker and is pushing for changes at the company.
Pfizer, yielding 5.6%, is an Ultra SWAN bargain with upside potential in the next year. Despite $70 billion in debt, Pfizer's A- credit rating and stable cash flow ensure long-term stability and very strong dividend safety. Pfizer's growth outlook includes a 5% long-term growth rate, with a 10% to 11% long-term return potential.
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
Pfizer's stock has likely bottomed and shows strong technical and fundamental indicators, including a "Golden Cross" and robust cost reduction plans. The company's promising pipeline, including weight-loss treatments and AI-driven drug discovery, offers significant long-term upside potential. The Seagen acquisition enhances Pfizer's cancer treatment portfolio, positioning it well in a high-demand sector.
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
Starboard Value has taken a $1 billion stake in drugmaker Pfizer. The hedge fund, headed by Jeff Smith, has become one of the most feared activist investors.
Evan David Seigerman, BMO Biotech Analyst, joins 'Closing Bell Overtime' to talk Pfizer shares climbing on activist firm Starboard taking a stake in the company.
Starboard takes a $1 billion stake in $PFE. It's our Chart Of The Day.
Pharmaceutical giant Pfizer (PFE) is seeing stock gains in Monday's pre-market trading after activist investor Starboard Value took up a $1 billion stake, according to a Wall Street Journal report. Yahoo Finance senior health reporter Anjalee Khemlani covers Starboard's reported investment in Pfizer as the pharma company seeks to reposition itself coming out of the COVID-19 pandemic.
Pfizer (PFE, Financial) stock saw a notable increase of 2.94% attributed to a reported $1 billion investment by activist investor Starboard Value. This strategic move is intended to breathe new life into Pfizer, as the stock has experienced a substantial decrease from its highs during the pandemic era.
Can Starboard Value and former CEO Ian Read save Pfizer stock?